Company intelligence / Profile preview

Meyer Pharmaceuticals Ltd.

Tuen Mun, New Territories, Hong Kong SAR Chinatandfonline.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company has sponsored at least one Phase 2 clinical trial comparing systemic chemotherapy to immunotherapy in unresectable/metastatic pancreatic cancer. Another drug candidate, MP–8 targeting MMP8 for arthritis, appears to be in preclinical or pending status. No published results from completed pivotal trials were found.

Therapeutic areas: OncologyRheumatology
Modalities: Small molecules (based on pipeline drug MP-8)possible biologics/immunotherapies
Industry: Biotech

Drug pipeline

1 asset

cytoimplant

Beyond the preview

Go deeper on Meyer Pharmaceuticals Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meyer Pharmaceuticals Ltd..

Explore the full profile